Evidence map›Paper›PMID 27352607›Full record

ArticleParasites & vectors2016

Evaluation of fluralaner and afoxolaner treatments to control flea populations, reduce pruritus and minimize dermatologic lesions in naturally infested dogs in private residences in west central Florida USA.

Michael W Dryden, Michael S Canfield, Kimberly Kalosy, Amber Smith, Lisa Crevoiserat, Jennifer C McGrady, Kaitlin M Foley, Kathryn Green, Chantelle Tebaldi, Vicki Smith and 5 more

Open access · goldAbstract read
In one paragraph

Article in Parasites & vectors, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Treatment of Animal Tungiasis: What's New?Tropical medicine and infectious disease · 2023
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Michael W DrydenDepartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA. Dryden@vet.k-state.edu.
Michael S CanfieldAnimal Dermatology South, 7741 Congress St, New Port Richey, FL, 34653, USA.
Kimberly KalosyDepartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA.
Amber SmithDepartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA.
Lisa CrevoiseratDepartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA.
Jennifer C McGradyDepartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA.
Kaitlin M FoleyDepartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA.
Kathryn GreenAnimal Dermatology South, 7741 Congress St, New Port Richey, FL, 34653, USA.
Chantelle TebaldiAnimal Dermatology South, 7741 Congress St, New Port Richey, FL, 34653, USA.
Vicki SmithDepartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA.
Tashina BennettDepartment of Diagnostic Medicine/Pathobiology, Kansas State University, Manhattan, KS, 66506, USA.
Kathleen HeaneyMerck Animal Health, 2 Giralda Farms, Madison, NJ, 07940, USA.
Lisa MathMerck Animal Health, 2 Giralda Farms, Madison, NJ, 07940, USA.
Christine RoyalMerck Animal Health, 2 Giralda Farms, Madison, NJ, 07940, USA.
Fangshi SunMerck Animal Health, 2 Giralda Farms, Madison, NJ, 07940, USA.
Kansas State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundA study was conducted to evaluate and compare the effectiveness of two different oral flea and tick products to control flea infestations, reduce pruritus and minimize dermatologic lesions over a 12 week period on naturally infested dogs in west central FL USA.

methodsThirty-four dogs with natural flea infestations living in 17 homes were treated once with a fluralaner chew on study day 0. Another 27 dogs living in 17 different homes were treated orally with an afoxolaner chewable on day 0, once between days 28-30 and once again between days 54-60. All products were administered according to label directions by study investigators. Flea populations on pets were assessed using visual area counts and premise flea infestations were assessed using intermittent-light flea traps on days 0, 7, 14, 21, and once between days 28-30, 40-45, 54-60 and 82-86. Dermatologic assessments were conducted on day 0 and once monthly. Pruritus assessments were conducted by owners throughout the study. No concurrent treatments for existing skin disease (antibiotics, anti-inflammatories, anti-fungals) were allowed.

resultsFollowing the first administration of fluralaner or afoxolaner, flea populations on pets were reduced by 99.0 % and 99.3 %, respectively within 7 days. Flea populations on the fluralaner treated dogs were 0 (100 % efficacy) on days 54-60 and 82-86 after the administration of a single dose on day 0. Administration of 3 monthly doses of afoxolaner reduced flea populations by 100 % on days 82-86. Flea numbers in indoor-premises were markedly reduced in both treatment groups by days 82-86, with 100 % and 98.9 % reductions in flea trap counts in the fluralaner and afoxolaner treatment groups, respectively. Marked improvement was observed in FAD lesion scoring, Atopic Dermatitis lesions scoring (CADESI-4) and pruritus scores with both formulations.

conclusionsIn a clinical field investigation conducted during the summer of 2015 in subtropical Florida, a single administration of an oral fluralaner chew completely eliminated dog and premises flea infestations and markedly reduced dermatology lesions and pruritus. Three monthly doses of the afoxolaner chewable also eliminated flea infestations in dogs, markedly reduced premises' flea populations and similarly improved dermatology lesions and pruritus.

Indexed as

AnimalsDog DiseasesDogsFlea InfestationsFloridaInsecticidesIsoxazolesNaphthalenesPruritusSiphonapteraA1443 compoundafoxolanerInsecticidesIsoxazolesNaphthalenesAfoxolanerAtopic DermatitisCat fleaCtenocephalides felis felisDogsField studyFleaFlea Allergy DermatitisFlea Bite DermatitisFlea controlFluralanerPruritus

Identifiers

PMID27352607
PMCPMC4924230
OpenAlexW2466804365

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.